Lexicon Pharmaceuticals (LXRX) News Today $1.44 -0.06 (-3.69%) As of 11:55 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Lexicon Pharmaceuticals Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy3 hours ago | globenewswire.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Stock Rated "Hold" by Sell-Side BrokeragesOctober 23 at 4:13 AM | marketbeat.comLexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular DiseaseOctober 21 at 11:27 PM | finance.yahoo.comLexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin's Biological Effects in Cardiovascular DiseaseOctober 21 at 8:30 AM | globenewswire.comLexicon Pharmaceuticals (NASDAQ:LXRX) Stock Falls 5.2% - What's Next?October 5, 2026 | marketbeat.comLexicon Pharmaceuticals consensus price target increased by 17.91% to $4.64October 2, 2026 | msn.comLexicon Pharmaceuticals (LXRX) Stock Fair Value Rises After SONATA HCM Trial ProgressOctober 2, 2026 | finance.yahoo.comLexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And MoreSeptember 30, 2026 | seekingalpha.comLexicon Pharmaceuticals bondit après une initiation favorable de Cantor FitzgeraldSeptember 29, 2026 | fr.finance.yahoo.comLexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathySeptember 28, 2026 | seekingalpha.comAktien von Lexicon Pharmaceuticals steigen nach Aufnahme der Beobachtung durch Cantor Fitzgerald mit Overweight-EinstufungSeptember 28, 2026 | de.marketscreener.comDLexicon Pharmaceuticals Shares Rise After Cantor Fitzgerald Initiates With Overweight RatingSeptember 28, 2026 | marketscreener.comMWhy Lexicon Pharmaceuticals Stock Popped by Almost 6% TodaySeptember 28, 2026 | fool.comWhy Lexicon Pharmaceuticals Stock Popped by Almost 6% TodaySeptember 28, 2026 | fool.comLexicon Pharmaceuticals stijgt fors nu Cantor Fitzgerald onbelemmerde weg ziet bij HCMSeptember 28, 2026 | nl.investing.comSaham Lexicon Pharmaceuticals melonjak usai Cantor Fitzgerald beri prospek cerah di HCMSeptember 28, 2026 | id.investing.comLexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCMSeptember 28, 2026 | ca.finance.yahoo.comLexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Up - What's Next?September 28, 2026 | marketbeat.comCantor Fitzgerald Initiates Lexicon Pharmaceuticals at Overweight With $8 Price TargetSeptember 28, 2026 | marketscreener.comMLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of "Hold" from BrokeragesSeptember 28, 2026 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at Cantor FitzgeraldSeptember 28, 2026 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Trading Down 7.5% - What's Next?September 24, 2026 | marketbeat.comLexicon Pharmaceuticals, Inc. (LXRX) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeptember 9, 2026 | seekingalpha.comLexicon Pharmaceuticals to Participate at Three Upcoming Investor ConferencesSeptember 1, 2026 | globenewswire.comLexicon's Sotagliflozin Shows Consistent Benefit For Heart Failure In Phase 3 Post-Hoc DataAugust 31, 2026 | rttnews.comLexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart ...August 31, 2026 | markets.businessinsider.comLexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart FailureAugust 31, 2026 | globenewswire.comLexicon Pharmaceuticals, Inc. (LXRX)August 29, 2026 | finance.yahoo.comLexicon Pharmaceuticals Gets $10 Million Novo Nordisk Milestone Payment for LX9851August 24, 2026 | finance.yahoo.comLexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851August 24, 2026 | globenewswire.comLexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage AssetsAugust 19, 2026 | seekingalpha.comLexicon (LXRX) Q2 2026 Earnings Call TranscriptAugust 13, 2026 | finance.yahoo.comLexicon Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call PresentationAugust 10, 2026 | seekingalpha.comLexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call TranscriptAugust 6, 2026 | seekingalpha.comLexicon: Q2 Earnings SnapshotAugust 6, 2026 | chron.comLexicon Pharmaceuticals Reports Q2 2026 Results; Completes Enrollment in Phase 3 SONATA-HCM Study and Advances ZYNQUISTA NDA ResubmissionAugust 6, 2026 | quiverquant.comQLexicon Pharmaceuticals Q2 revenue falls to $0.7 million amid clinical updatesAugust 6, 2026 | quiverquant.comQLexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical UpdatesAugust 6, 2026 | globenewswire.comLexicon Pharmaceuticals Q2 2026 earnings previewAugust 5, 2026 | msn.comLexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026July 30, 2026 | globenewswire.comLexicon Pharmaceuticals (LXRX) As Phase 3 Enrollment Beats Plan Faces An Undervalued ViewJuly 30, 2026 | finance.yahoo.comLexicon Pharmaceuticals: Advancing Cardiometabolic Pipeline and Phase 3 HCM Data Support Unchanged $6 Price Target and Buy RatingJuly 27, 2026 | tipranks.comLexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)July 27, 2026 | globenewswire.comLexicon Pharmaceuticals (LXRX) Gains on Russell 3000 InclusionJuly 3, 2026 | insidermonkey.comIs Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now?June 11, 2026 | finance.yahoo.comHow The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst UpdatesJune 4, 2026 | finance.yahoo.comLexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific SessionsJune 3, 2026 | globenewswire.comLexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comSA analyst upgrades/downgrades: SMCI, AMZN, SFM, LXRXMay 27, 2026 | msn.comLexicon Pharmaceuticals: Uncertainty Clouds The Bull Case (Rating Downgrade)May 26, 2026 | seekingalpha.com Lexicon Pharmaceuticals Media Mentions By Week Lexicon Pharmaceuticals Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXRX News Sentiment▼0.000.47▲Average Healthcare News Sentiment Lexicon Pharmaceuticals News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXRX Articles This Week▼44▲LXRX Articles Average Week Lexicon Pharmaceuticals Trends on MarketBeatThis week vs. last weekNew Followers1Searches3+200%Page Views2,382-12% Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies NRIX News DYN News ZLAB News BEAM News ADMA News NAMS News PGEN News AUPH News IRON News CLDX News News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Lexicon Pharmaceuticals dated 10/23/2026. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
